Kymera Therapeutics, Inc.
corporate_fare Company Profile
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for KYMR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for KYMR spans 8-K, 10-Q, 4, SCHEDULE 13D/A.
Recent high-impact activity:
- Kymera Q3 Loss Widens to $132M; KT-579 Phase 1 Achieves ≥90% IRF5 Degradation
- Kymera Posts $1.32 Per-Share Q3 Loss as KT-621 Data Looms
- Kymera Eyes Alzheimer's Data by Year-End, Phase 3 Start in 2027
- Kymera Q2 2026: $65M Revenue, $1.5B Cash, Runway Into 2029
- Kymera Q2 2026: KT-621 Phase 2b Enrollment Completed Early, Data by Year-End; $1.5B Cash Runway into 2029
Financial Snapshot
Short Interest & Short Volume
10.49 days to coverFINRA reported short interest of 8,400,784 shares in KYMR as of the October 30, 2026 settlement, a 8.4% decrease from the prior period — about 10.5 days to cover at its recent average daily volume. On November 20, 2026, 42.3% of KYMR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.